

Alexandre Chan

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9284150/alexandre-chan-publications-by-year.pdf>

Version: 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

228
papers

4,091
citations

35
h-index

53
g-index

254
ext. papers

5,062
ext. citations

3.5
avg, IF

5.66
L-index

#	Paper	IF	Citations
228	Reporting adherence, validity and physical activity measures of wearable activity trackers in medical research: A systematic review.. <i>International Journal of Medical Informatics</i> , 2022 , 160, 104696	5.3	4
227	Barriers and facilitators to exercise among adult cancer survivors in Singapore.. <i>Supportive Care in Cancer</i> , 2022 , 1	3.9	1
226	Dual contribution of the gut microbiome to immunotherapy efficacy and toxicity: supportive care implications and recommendations.. <i>Supportive Care in Cancer</i> , 2022 , 1	3.9	1
225	Adherence to Cancer Survivorship Care Guidelines and Health Care Utilization Patterns Among Nonmetastatic Breast Cancer Survivors in Singapore.. <i>JCO Global Oncology</i> , 2022 , 8, e2100246	3.7	
224	Implementing a community-based shared care breast cancer survivorship model in Singapore: a qualitative study among primary care practitioners. 2022 , 23, 73		
223	Health Disparities in Pharmacy Practice Within the Community: Let's Brainstorm for Solutions.. <i>Frontiers in Public Health</i> , 2022 , 10, 847696	6	0
222	International society of oncology pharmacy practitioners (ISOPP) position statement: The role of oncology pharmacy practitioners in immunotherapy treatment with immune checkpoint inhibitors for malignant conditions.. <i>Journal of Oncology Pharmacy Practice</i> , 2022 , 10781552221090199	1.7	
221	Pharmacological Treatment of Established Chemotherapy-Induced Peripheral Neuropathy 2021 , 155-181		0
220	Impact of coronavirus of 2019 on the delivery of pharmacy services to patients with cancer: An international survey of oncology pharmacy practitioners. <i>Journal of Oncology Pharmacy Practice</i> , 2021 , 10781552211048892	1.7	
219	Older adult and family caregiver experiences with prescription medication labels and their suggestions for label improvement.. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2021 , 4, 100087		0
218	International Society of Oncology Pharmacy Practitioners (ISOPP) position statement: Role of the oncology pharmacy team in cancer care. <i>Journal of Oncology Pharmacy Practice</i> , 2021 , 27, 785-801	1.7	6
217	ICES (International Carboplatin Emesis Survey) for the evaluation of the emetogenicity of continuous cycles of carboplatin-based chemotherapy with focus on nausea: A MASCC emesis study group, prospective, observational, real-world multi-centric study.. <i>Journal of Clinical Oncology</i> , 2021 , 39, e24086-e24086	2.2	
216	Pharmacogenomics Implementation Training Improves Self-Efficacy and Competency to Drive Adoption in Clinical Practice. <i>Frontiers in Pharmacology</i> , 2021 , 12, 684907	5.6	0
215	Validation of pharmaceutical pictograms among older adults with limited English proficiency. <i>Patient Education and Counseling</i> , 2021 ,	3.1	1
214	Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group. <i>Supportive Care in Cancer</i> , 2021 , 29, 2821-2840	3.9	15
213	Extracellular Vesicle Proteome of Breast Cancer Patients with and Without Cognitive Impairment Following Anthracycline-based Chemotherapy: An Exploratory Study. <i>Biomarker Insights</i> , 2021 , 16, 11772719211018204	3.5	1
212	Clinical and economic evaluation of a surveillance protocol to manage hepatitis B virus (HBV) reactivation among lymphoma patients with resolved HBV infection receiving rituximab. <i>Pharmacotherapy</i> , 2021 , 41, 332-341	5.8	2

211	Investigating how cancer-related symptoms influence work outcomes among cancer survivors: a systematic review. <i>Journal of Cancer Survivorship</i> , 2021 , 1	5.1	2
210	Distinct employment interference profiles in patients with breast cancer prior to and for 12 months following surgery. <i>BMC Cancer</i> , 2021 , 21, 883	4.8	0
209	Relationship between cytokines and brain-derived neurotrophic factor (BDNF) in trajectories of cancer-related cognitive impairment. <i>Cytokine</i> , 2021 , 144, 155556	4	3
208	The use of patient-reported outcomes in routine cancer care: preliminary insights from a multinational scoping survey of oncology practitioners. <i>Supportive Care in Cancer</i> , 2021 , 1	3.9	3
207	The efficacy, challenges, and facilitators of telemedicine in post-treatment cancer survivorship care: an overview of systematic reviews. <i>Annals of Oncology</i> , 2021 , 32, 1552-1570	10.3	12
206	Characteristics associated with inter-individual variability in financial distress in patients with breast cancer prior to and for 12 months following surgery. <i>Supportive Care in Cancer</i> , 2021 , 1	3.9	1
205	Current and recommended practices for evaluating adverse drug events using electronic health records: A systematic review. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021 , 4, 1457	1.4	0
204	Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN). <i>Cancer Treatment Reviews</i> , 2021 , 99, 102241	14.4	7
203	Adverse lifestyle behaviors among childhood cancer survivors with cognitive impairment: The Project Forward Cohort.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 138-138	2.2	
202	Range, effectiveness, and implementation of decision aids supporting cancer survivors' decisions over health services participation in the post-treatment phase: A systematic review.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 203-203	2.2	0
201	Baseline characteristics of breast and gynecological cancer patients enrolled in the trial of a multidisciplinary survivorship care model in an Asian national ambulatory cancer center.. <i>Journal of Clinical Oncology</i> , 2021 , 39, 37-37	2.2	
200	Cancer-related cognitive impairment is associated with perturbations in inflammatory pathways. <i>Cytokine</i> , 2021 , 148, 155653	4	5
199	24. An analysis of the National Institutes of Health All of Us Research Database: Sociodemographic Disparities Among Patients Who Received Vaccinations. <i>Open Forum Infectious Diseases</i> , 2021 , 8, S135-S136		1
198	Assessing biosimilar education needs among oncology pharmacy practitioners worldwide: An ISOPP membership survey. <i>Journal of Oncology Pharmacy Practice</i> , 2020 , 26, 11-21	1.7	2
197	Advances and future directions in the use of mobile health in supportive cancer care: proceedings of the 2019 MASCC Annual Meeting symposium. <i>Supportive Care in Cancer</i> , 2020 , 28, 4059-4067	3.9	11
196	Global oncology pharmacy response to COVID-19 pandemic: Medication access and safety. <i>Journal of Oncology Pharmacy Practice</i> , 2020 , 26, 1225-1229	1.7	8
195	A survey of global biosimilar implementation practice conducted by the International Society of Oncology Pharmacy Practitioners. <i>Journal of Oncology Pharmacy Practice</i> , 2020 , 26, 22-32	1.7	4
194	Optimizing Survivorship Care Services for Asian Adolescent and Young Adult Cancer Survivors: A Qualitative Study. <i>Journal of Adolescent and Young Adult Oncology</i> , 2020 , 9, 384-393	2.2	2

193	Self-reported cognitive outcomes among adolescent and young adult patients with noncentral nervous system cancers. <i>Psycho-Oncology</i> , 2020 , 29, 1355-1362	3.9	4
192	Roles and recommendations from primary care physicians towards managing low-risk breast cancer survivors in a shared-care model with specialists in Singapore-a qualitative study. <i>Family Practice</i> , 2020 , 37, 547-553	1.9	3
191	A longitudinal analysis of phenotypic and symptom characteristics associated with inter-individual variability in employment interference in patients with breast cancer. <i>Supportive Care in Cancer</i> , 2020 , 28, 4677-4686	3.9	7
190	Distinct cytokine profiles across trajectories of self-perceived cognitive impairment among early-stage breast cancer survivors. <i>Journal of Neuroimmunology</i> , 2020 , 342, 577196	3.5	6
189	Work- and insurance-related issues among Asian adolescent and young-adult cancer survivors: a qualitative study. <i>Supportive Care in Cancer</i> , 2020 , 28, 5901-5909	3.9	2
188	Role of Exosomes in Cancer-Related Cognitive Impairment. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	9
187	Distinct financial distress profiles in patients with breast cancer prior to and for 12 months following surgery. <i>BMJ Supportive and Palliative Care</i> , 2020 ,	2.2	8
186	Feasibility, delivery, and acceptance of a multidisciplinary survivorship care model based in an Asian national ambulatory cancer center: A six-month review.. <i>Journal of Clinical Oncology</i> , 2020 , 38, 34-34	2.2	
185	Impact of a pharmacist-led education and follow-up service on anticoagulation control and safety outcomes at a tertiary hospital in China: a randomised controlled trial. <i>International Journal of Pharmacy Practice</i> , 2020 , 28, 97-106	1.7	3
184	Pharmacy students' perceptions toward peer assessment and its use in teaching patient presentation skills. <i>Currents in Pharmacy Teaching and Learning</i> , 2020 , 12, 228-236	1.5	3
183	2019 Update to the American College of Clinical Pharmacy Pharmacotherapy Didactic Curriculum Toolkit. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2020 , 3, 455-464	1.4	18
182	HPLC-MS/MS coupled with equilibrium dialysis method for quantification of free drug concentration of pazopanib in plasma. <i>Heliyon</i> , 2020 , 6, e03813	3.6	3
181	A study protocol for HEalth-Related quality of life-intervention in survivors of Breast and other cancers experiencing cancer-related fatigue using TraditionAL Chinese Medicine: the HERBAL trial. <i>Trials</i> , 2020 , 21, 909	2.8	0
180	Associations of plasma brain-derived neurotrophic factor (BDNF) and Val66Met polymorphism (rs6265) with long-term cancer-related cognitive impairment in survivors of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020 , 183, 683-696	4.4	2
179	Association of mitochondrial DNA content and displacement loop region sequence variations with cancer-related fatigue in breast cancer survivors receiving chemotherapy. <i>Mitochondrion</i> , 2020 , 54, 65-74	4.9	0
178	Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy. <i>Health and Quality of Life Outcomes</i> , 2020 , 18, 246	3	8
177	Impact of Cryotherapy on Sensory, Motor, and Autonomic Neuropathy in Breast Cancer Patients Receiving Paclitaxel: A Randomized, Controlled Trial. <i>Frontiers in Neurology</i> , 2020 , 11, 604688	4.1	3
176	International Society of Oncology Pharmacy Practitioners global position on the use of biosimilars in cancer treatment and supportive care. <i>Journal of Oncology Pharmacy Practice</i> , 2020 , 26, 3-10	1.7	3

175	Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. <i>Brain and Behavior</i> , 2019 , 9, e01312	3.4	42
174	Association of plasma leptin, pro-inflammatory adipokines and cancer-related fatigue in early-stage breast cancer patients: A prospective cohort study. <i>Journal of Cellular and Molecular Medicine</i> , 2019 , 23, 4281-4289	5.6	6
173	Prechemotherapy Levels of Plasma Dehydroepiandrosterone and Its Sulfated Form as Predictors of Cancer-Related Cognitive Impairment in Patients with Breast Cancer Receiving Chemotherapy. <i>Pharmacotherapy</i> , 2019 , 39, 553-563	5.8	3
172	Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy. <i>Supportive Care in Cancer</i> , 2019 , 27, 4753-4762	3.9	14
171	Managing Pharmacotherapy in People Living With HIV and Concomitant Malignancy. <i>Annals of Pharmacotherapy</i> , 2019 , 53, 812-832	2.9	7
170	Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. <i>BMC Cancer</i> , 2019 , 19, 132	4.8	75
169	Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study. <i>Supportive Care in Cancer</i> , 2019 , 27, 1109-1119	3.9	12
168	Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview. <i>Supportive Care in Cancer</i> , 2019 , 27, 3729-3737	3.9	34
167	Optimizing Vancomycin Dosing in Chronic Kidney Disease by Deriving and Implementing a Web-Based Tool Using a Population Pharmacokinetics Analysis. <i>Frontiers in Pharmacology</i> , 2019 , 10, 641	5.6	3
166	An Evaluation of DNA Methyltransferase 1 (DNMT1) Single Nucleotide Polymorphisms and Chemotherapy-Associated Cognitive Impairment: A Prospective, Longitudinal Study. <i>Scientific Reports</i> , 2019 , 9, 14570	4.9	8
165	Perception of electronic peer review of SOAP notes among pharmacy students enrolling in their first pharmacotherapeutics course. <i>Currents in Pharmacy Teaching and Learning</i> , 2019 , 11, 1259-1264	1.5	3
164	Relationships Between Financial Toxicity and Symptom Burden in Cancer Survivors: A Systematic Review. <i>Journal of Pain and Symptom Management</i> , 2019 , 57, 646-660.e1	4.8	51
163	Replication and Meta-analysis of the Association between BDNF Val66Met Polymorphism and Cognitive Impairment in Patients Receiving Chemotherapy. <i>Molecular Neurobiology</i> , 2019 , 56, 4741-4750	6.2	12
162	Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults. <i>Pharmacogenomics Journal</i> , 2019 , 19, 401-410	3.5	5
161	Management of hepatitis B reactivation in lymphoma patients on rituximab with past hepatitis B exposure: An observational study. <i>Journal of Oncology Pharmacy Practice</i> , 2019 , 25, 1042-1052	1.7	4
160	Distinct and heterogeneous trajectories of self-perceived cognitive impairment among Asian breast cancer survivors. <i>Psycho-Oncology</i> , 2018 , 27, 1185-1192	3.9	25
159	Association of mitochondrial DNA content in peripheral blood with cancer-related fatigue and chemotherapy-related cognitive impairment in early-stage breast cancer patients: a prospective cohort study. <i>Breast Cancer Research and Treatment</i> , 2018 , 168, 713-721	4.4	10
158	Assessment of psychological distress among Asian adolescents and young adults (AYA) cancer patients using the distress thermometer: a prospective, longitudinal study. <i>Supportive Care in Cancer</i> , 2018 , 26, 3257-3266	3.9	10

157	Survivorship care models for breast cancer, colorectal cancer, and adolescent and young adult (AYA) cancer survivors: a systematic review. <i>Supportive Care in Cancer</i> , 2018 , 26, 2125-2141	3.9	12
156	Implementing Clinical Prediction Models: Pushing the Needle Towards Precision Pharmacotherapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018 , 103, 180-183	6.1	5
155	Psychometric properties and measurement equivalence of the Multidimensional Fatigue Syndrome Inventory- Short Form (MFSI-SF) amongst breast cancer and lymphoma patients in Singapore. <i>Health and Quality of Life Outcomes</i> , 2018 , 16, 20	3	5
154	Breast cancer screening behavior, attitude, barriers among middle-aged Chinese women in Macao, China. <i>Journal of Public Health</i> , 2018 , 40, e560-e570	3.5	5
153	A response to the letter to the editor on "Management of hepatitis B reactivation in lymphoma patients on rituximab with past hepatitis B exposure: An observational study". <i>Journal of Oncology Pharmacy Practice</i> , 2018 , 24, 478-479	1.7	1
152	Gut microbiome alterations in breast cancer survivors with cancer-related fatigue.. <i>Journal of Clinical Oncology</i> , 2018 , 36, e22178-e22178	2.2	2
151	Practitioners' perspectives on community-based breast cancer survivorship care in Singapore: A focus group study. <i>Health and Social Care in the Community</i> , 2018 , 26, 404-411	2.6	2
150	Minimal Clinically Important Difference of the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) for Fatigue Worsening in Asian Breast Cancer Patients. <i>Journal of Pain and Symptom Management</i> , 2018 , 55, 992-997.e2	4.8	15
149	Cancer Supportive and Survivorship Care in Singapore: Current Challenges and Future Outlook. <i>Journal of Global Oncology</i> , 2018 , 4, 1-8	2.6	8
148	Thalidomide for Delayed Chemotherapy-Induced Nausea and Vomiting: Where Is Its Place in Therapy?. <i>Journal of Clinical Oncology</i> , 2018 , 36, 827-828	2.2	1
147	Impact of Adjuvant Anthracycline-Based and Taxane-Based Chemotherapy on Plasma VEGF Levels and Cognitive Function in Breast Cancer Patients: A Longitudinal Study. <i>Clinical Breast Cancer</i> , 2018 , 18, e927-e937	3	10
146	Chemotherapy-associated cognitive impairments in Korean cancer patients: Risk factors and functional outcome. <i>Psycho-Oncology</i> , 2018 , 27, 1995-2001	3.9	5
145	Impact of brain-derived neurotrophic factor genetic polymorphism on cognition: A systematic review. <i>Brain and Behavior</i> , 2018 , 8, e01009	3.4	47
144	Chemotherapy drug concentrations in hair follicles: a potential biomarker to monitor the effectiveness of scalp cooling for chemotherapy-induced alopecia. <i>Supportive Care in Cancer</i> , 2018 , 26, 3669-3670	3.9	2
143	Pharmacists' roles in oncology pharmacy services: Results of a global survey. <i>Journal of Oncology Pharmacy Practice</i> , 2017 , 23, 185-194	1.7	23
142	Chemotherapy regimen checks performed by pharmacists contribute to safe administration of chemotherapy. <i>Journal of Oncology Pharmacy Practice</i> , 2017 , 23, 18-25	1.7	16
141	Identifying Potentially Avoidable Readmissions: A Medication-Based 15-Day Readmission Risk Stratification Algorithm. <i>Pharmacotherapy</i> , 2017 , 37, 268-277	5.8	18
140	HbA1c variability in type 2 diabetes is associated with the occurrence of new-onset albuminuria within three years. <i>Diabetes Research and Clinical Practice</i> , 2017 , 128, 32-39	7.4	9

139	Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions. <i>Current Oncology Reports</i> , 2017 , 19, 20	6.3	5
138	The prognostic performance of adding patient-reported outcomes to the MASCC risk index to identify low-risk febrile neutropenia patients with solid tumors and lymphomas. <i>Supportive Care in Cancer</i> , 2017 , 25, 2815-2822	3.9	4
137	Role of Procalcitonin in Differentiating between Infectious and Noninfectious Fevers among Patients with Lymphoma. <i>Pharmacotherapy</i> , 2017 , 37, 908-915	5.8	1
136	Evaluation of plasma brain-derived neurotrophic factor levels and self-perceived cognitive impairment post-chemotherapy: a longitudinal study. <i>BMC Cancer</i> , 2017 , 17, 867	4.8	18
135	Perceptions and Barriers of Survivorship Care in Asia: Perceptions From Asian Breast Cancer Survivors. <i>Journal of Global Oncology</i> , 2017 , 3, 98-104	2.6	7
134	Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement. <i>Journal of Global Oncology</i> , 2017 , 3, 881-888	2.6	4
133	A culturally adapted survivorship programme for Asian early stage breast cancer patients in Singapore: A randomized, controlled trial. <i>Psycho-Oncology</i> , 2017 , 26, 1654-1659	3.9	12
132	Long-term Clinical and Cost Outcomes of a Pharmacist-managed Risk Factor Management Clinic in Singapore: An Observational Study. <i>Clinical Therapeutics</i> , 2017 , 39, 2355-2365	3.5	2
131	Therapeutic Use of Filgrastim for Established Febrile Neutropenia Is Cost Effective Among Patients With Solid Tumors and Lymphomas. <i>Clinical Therapeutics</i> , 2017 , 39, 1161-1170	3.5	2
130	Psychometric properties and measurement equivalence of the English and Chinese versions of the Beck Anxiety Inventory in patients with breast cancer. <i>Supportive Care in Cancer</i> , 2017 , 25, 633-643	3.9	14
129	2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. <i>Supportive Care in Cancer</i> , 2017 , 25, 271-275	3.9	18
128	2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy. <i>Supportive Care in Cancer</i> , 2017 , 25, 277-288	3.9	72
127	Mitochondrial DNA content in peripheral blood as a biomarker for cancer-related fatigue in early-stage breast cancer patients: A prospective cohort study.. <i>Journal of Clinical Oncology</i> , 2017 , 35, 10018-10018	2.2	1
126	A genome-wide association study (GWAS) meta-analysis of chemotherapy-associated cognitive impairment (CACI) in Asian early-stage breast cancer patients (ESBC).. <i>Journal of Clinical Oncology</i> , 2017 , 35, 10096-10096	2.2	1
125	A web-based tool to predict chemotherapy-associated cognitive impairment during survivorship.. <i>Journal of Clinical Oncology</i> , 2017 , 35, e21609-e21609	2.2	1
124	Assessment of mental health literacy in patients with breast cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2016 , 22, 437-47	1.7	15
123	Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients. <i>Pharmacogenomics Journal</i> , 2016 , 16, 47-53	3.5	22
122	Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 1636-1646	3.8	44

121	Medication use by early-stage breast cancer survivors: a 1-year longitudinal study. <i>Supportive Care in Cancer</i> , 2016 , 24, 1639-47	3.9	3
120	Exercise improves quality of life in androgen deprivation therapy-treated prostate cancer: systematic review of randomised controlled trials. <i>Endocrine-Related Cancer</i> , 2016 , 23, 101-12	5.7	38
119	Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma. <i>Acta Oncologica</i> , 2016 , 55, 519-20	3.2	44
118	Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer. <i>Neuro-Oncology</i> , 2016 , 18, 244-51	1	56
117	Perceptions of pharmacy students and pharmacists on SOAP note education and utility in pharmacy practice. <i>Currents in Pharmacy Teaching and Learning</i> , 2016 , 8, 77-82	1.5	3
116	Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting: Development and External Validation of a Nomogram in Cancer Patients Receiving Highly/Moderately Emetogenic Chemotherapy. <i>Medicine (United States)</i> , 2016 , 95, e2476	1.8	13
115	What are the barriers of quality survivorship care for haematology cancer patients? Qualitative insights from cancer nurses. <i>Journal of Cancer Survivorship</i> , 2016 , 10, 122-30	5.1	10
114	Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy. <i>PLoS ONE</i> , 2016 , 11, e0148901	3.7	4
113	Impact of TNF- α (rs1800629) and IL-6 (rs1800795) Polymorphisms on Cognitive Impairment in Asian Breast Cancer Patients. <i>PLoS ONE</i> , 2016 , 11, e0164204	3.7	29
112	Psychometric Properties of the Functional Assessment of Cancer Therapy-Neutropenia in Asian Cancer Patients With Chemotherapy-Induced Neutropenia. <i>Journal of Pain and Symptom Management</i> , 2016 , 52, 428-36	4.8	3
111	Impact of chemotherapy on cancer-related fatigue and cytokines in 1312 patients: a systematic review of quantitative studies. <i>Current Opinion in Supportive and Palliative Care</i> , 2016 , 10, 165-79	2.6	17
110	Recommendations for Aligning PGY2 Pharmacy Residency Training and Pharmacy Specialist Board Certification. <i>Pharmacotherapy</i> , 2016 , 36, e34-9	5.8	3
109	BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen. <i>Cancer Chemotherapy and Pharmacology</i> , 2016 , 78, 623-32	3.5	7
108	Underdiagnosis of depression in an economically deprived population in Macao, China. <i>Asia-Pacific Psychiatry</i> , 2016 , 8, 70-9	3.2	7
107	Incidence and Management of Toxicity Associated with LAsparaginase in the Treatment of ALL and NK/TCell Lymphoma: an Observational Study. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016 , 17, 3155-60	1.7	1
106	A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies. <i>Supportive Care in Cancer</i> , 2015 , 23, 2231-44	3.9	22
105	Symptom burden and medication use in adult sarcoma patients. <i>Supportive Care in Cancer</i> , 2015 , 23, 1709-17	3.9	17
104	Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice--a longitudinal analysis. <i>Supportive Care in Cancer</i> , 2015 , 23, 283-91	3.9	24

103	Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib. <i>Targeted Oncology</i> , 2015 , 10, 429-37	5	23
102	Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. <i>Supportive Care in Cancer</i> , 2015 , 23, 263-72	3.9	40
101	Rationale and design of the Pan Australasian chemotherapy-induced emesis burden of illness study. <i>Supportive Care in Cancer</i> , 2015 , 23, 253-61	3.9	7
100	Follow-up care practices and barriers to breast cancer survivorship: perspectives from Asian oncology practitioners. <i>Supportive Care in Cancer</i> , 2015 , 23, 3193-200	3.9	13
99	Systematic review of pharmacologic and non-pharmacologic interventions to manage cognitive alterations after chemotherapy for breast cancer. <i>European Journal of Cancer</i> , 2015 , 51, 437-450	7.5	45
98	Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore. <i>Clinical Genitourinary Cancer</i> , 2015 , 13, e285-e295	3.3	16
97	Carotid artery inflammation associated with gemcitabine-based therapy: a special report. <i>Future Oncology</i> , 2015 , 11, 2049-58	3.6	4
96	Trajectory and risk factors for chemotherapy-induced nausea and vomiting in Asian patients with head and neck cancer. <i>Head and Neck</i> , 2015 , 37, 1349-57	4.2	7
95	Impact of CINV in earlier cycles on CINV and chemotherapy regimen modification in subsequent cycles in Asia Pacific clinical practice. <i>Supportive Care in Cancer</i> , 2015 , 23, 293-300	3.9	16
94	Survivorship Care Provision for Patients With Hematologic Malignancies: The Quest for Quality Evidence. <i>Cancer Nursing</i> , 2015 , 38, 414-5	2.6	2
93	The Effect of Ginger (<i>Zingiber officinale</i>) on Platelet Aggregation: A Systematic Literature Review. <i>PLoS ONE</i> , 2015 , 10, e0141119	3.7	28
92	Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study. <i>Annals of Oncology</i> , 2015 , 26, 1446-51 ^{10.3}	10.3	134
91	Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2015 , 94, 201-12	7	17
90	Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. <i>British Journal of Clinical Pharmacology</i> , 2015 , 79, 241-53 ^{3.8}	3.8	81
89	Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy--a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines. <i>Supportive Care in Cancer</i> , 2015 , 23, 273-82	3.9	23
88	Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015 , 11, 231-42	5.5	39
87	Clinical efficacy of adjunctive G-CSF on solid tumor and lymphoma patients with established febrile neutropenia. <i>Supportive Care in Cancer</i> , 2014 , 22, 1105-12	3.9	10
86	Characteristics of unplanned hospital admissions due to drug-related problems in cancer patients. <i>Supportive Care in Cancer</i> , 2014 , 22, 1875-81	3.9	24

85	Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation. <i>Cancer Chemotherapy and Pharmacology</i> , 2014 , 73, 381-8	3.5	11
84	The genetic variants underlying breast cancer treatment-induced chronic and late toxicities: a systematic review. <i>Cancer Treatment Reviews</i> , 2014 , 40, 1199-214	14.4	25
83	The changing paradigm for supportive care in cancer patients. <i>Supportive Care in Cancer</i> , 2014 , 22, 1441-5	3.9	12
82	Technological preferences of aging cancer patients for delivery services and devices to solve drug-related problems in oncology. <i>Supportive Care in Cancer</i> , 2014 , 22, 2733-40	3.9	5
81	Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: cognitive function (FACT-Cog) in breast cancer patients. <i>Journal of Clinical Epidemiology</i> , 2014 , 67, 811-20	5.7	65
80	Management options for established chemotherapy-induced peripheral neuropathy. <i>Supportive Care in Cancer</i> , 2014 , 22, 2281-95	3.9	40
79	A Pilot Study to Evaluate the Role of Therapeutic Drug Monitoring of Pegfilgrastim in Lymphoma Patients Receiving Chemotherapy. <i>Proceedings of Singapore Healthcare</i> , 2014 , 23, 13-20	0.5	1
78	Costs associated with febrile neutropenia in solid tumor and lymphoma patients - an observational study in Singapore. <i>BMC Health Services Research</i> , 2014 , 14, 434	2.9	12
77	Minimum qualifications for clinical pharmacy practice faculty. <i>Pharmacotherapy</i> , 2014 , 34, e38-44	5.8	15
76	Vascular endothelial growth factor inhibitors and cognitive impairment: evidence and controversies. <i>Expert Opinion on Drug Safety</i> , 2014 , 13, 83-92	4.1	15
75	Costs and length of stay of drug-related hospital admissions in cancer patients. <i>Clinical Therapeutics</i> , 2014 , 36, 588-92	3.5	6
74	Association between clinical response and toxicities with drug exposure in an alternative dosing regimen of sunitinib.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 439-439	2.2	
73	Potentially inappropriate prescribing and drug-drug interactions among elderly Chinese nursing home residents in Macao. <i>International Journal of Clinical Pharmacy</i> , 2013 , 35, 805-12	2.3	22
72	Breakthrough febrile neutropenia and associated complications among elderly cancer patients receiving myelosuppressive chemotherapy for solid tumors and lymphomas. <i>Supportive Care in Cancer</i> , 2013 , 21, 2137-43	3.9	13
71	Exploring clinical determinants and anxiety symptom domains among Asian breast cancer patients. <i>Supportive Care in Cancer</i> , 2013 , 21, 2185-94	3.9	13
70	Acknowledging the relevance of cognitive changes in cancer patients: perspectives of oncology practitioners in Asia. <i>Journal of Cancer Survivorship</i> , 2013 , 7, 146-54	5.1	4
69	Affordability of cancer treatment for aging cancer patients in Singapore: an analysis of health, lifestyle, and financial burden. <i>Supportive Care in Cancer</i> , 2013 , 21, 3509-17	3.9	21
68	Impact of cancer-related fatigue on chemotherapy-induced nausea and vomiting in Asian cancer patients. <i>Pharmacoepidemiology and Drug Safety</i> , 2013 , 22, 1345-51	2.6	11

67	Linguistic validation of Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog): methodological concerns. <i>Supportive Care in Cancer</i> , 2013 , 21, 655-6	3.9	3
66	Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. <i>Supportive Care in Cancer</i> , 2013 , 21, 2933-48	3.9	146
65	Psychometric properties and measurement equivalence of the English and Chinese versions of the functional assessment of cancer therapy-cognitive in Asian patients with breast cancer. <i>Value in Health</i> , 2013 , 16, 1001-13	3.3	48
64	Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: a meta-analysis. <i>Cancer Treatment Reviews</i> , 2013 , 39, 199-206	14.4	65
63	Visualizing clinical predictors of febrile neutropenia in Asian cancer patients receiving myelosuppressive chemotherapy. <i>Journal of Oncology Pharmacy Practice</i> , 2013 , 19, 111-20	1.7	10
62	Clinical pharmacy services and research for lymphoma patients at a cancer center. <i>Journal of Oncology Pharmacy Practice</i> , 2013 , 19, 24-30	1.7	10
61	Feasibility and acceptance of a pharmacist-run tele-oncology service for chemotherapy-induced nausea and vomiting in ambulatory cancer patients. <i>Telemedicine Journal and E-Health</i> , 2013 , 19, 387-95	5.9	19
60	Cytokines as mediators of chemotherapy-associated cognitive changes: current evidence, limitations and directions for future research. <i>PLoS ONE</i> , 2013 , 8, e81234	3.7	47
59	Neuro-cognitive impairment in breast cancer patients: pharmacological considerations. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 83, 99-111	7	34
58	Aprepitant for Patients Receiving Highly Emetogenic Chemotherapy: An Economic Analysis for Singapore. <i>Value in Health Regional Issues</i> , 2012 , 1, 66-74	1.6	7
57	Health State Utility Assessment for Breast Cancer. <i>Value in Health Regional Issues</i> , 2012 , 1, 93-97	1.6	15
56	Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore. <i>Value in Health Regional Issues</i> , 2012 , 1, 46-53	1.6	6
55	Clinically-relevant anticancer-antidepressant drug interactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012 , 8, 173-99	5.5	11
54	Prevalence of the coprescription of clinically important interacting drug combinations involving oral anticancer agents in Singapore: a retrospective database study. <i>Clinical Therapeutics</i> , 2012 , 34, 1696-704	3.5	22
53	Clinical impact of drug-drug interaction between aspirin and prednisolone at a cancer center. <i>Clinical Therapeutics</i> , 2012 , 34, 2259-67	3.5	2
52	Conservative management of L-asparaginase-induced hypertriglyceridemia in an adult patient: a case report and review of the literature. <i>Onkologie</i> , 2012 , 35, 596-8		7
51	Assessment of the relationship between adherence with antiemetic drug therapy and control of nausea and vomiting in breast cancer patients receiving anthracycline-based chemotherapy. <i>Journal of Managed Care Pharmacy</i> , 2012 , 18, 385-94		30
50	Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy. <i>Supportive Care in Cancer</i> , 2012 , 20, 1525-32	3.9	38

49	An evaluation on the neuropsychological tests used in the assessment of postchemotherapy cognitive changes in breast cancer survivors. <i>Supportive Care in Cancer</i> , 2012 , 20, 1361-75	3.9	19
48	Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence. <i>Breast Cancer Research and Treatment</i> , 2012 , 133, 703-11	4.4	46
47	Dosing modifications of targeted cancer therapies in patients with special needs: evidence and controversies. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 81, 58-74	7	3
46	To SMILE or not: supportive care matters. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1015-6; author reply 1016-7	2.2	17
45	Antiemetic effectiveness and nausea and vomiting incidence during capecitabine and oxaliplatin chemotherapy. <i>Nursing Research</i> , 2012 , 61, 405-12	1.9	4
44	Computational prediction of state anxiety in Asian patients with cancer susceptible to chemotherapy-induced nausea and vomiting. <i>Journal of Clinical Psychopharmacology</i> , 2012 , 32, 207-17	1.7	21
43	Utilizing mobile networks for the detection of clinically relevant interactions between chemotherapy regimens and complementary and alternative medicines. <i>Journal of Alternative and Complementary Medicine</i> , 2012 , 18, 165-74	2.4	8
42	Cognitive changes in multiethnic Asian breast cancer patients: a focus group study. <i>Annals of Oncology</i> , 2012 , 23, 2547-2552	10.3	43
41	Effects of chemotherapy and psychosocial distress on perceived cognitive disturbances in Asian breast cancer patients. <i>Annals of Pharmacotherapy</i> , 2012 , 46, 1645-55	2.9	32
40	Exploring Chemotherapy-Induced Toxicities through Multivariate Projection of Risk Factors: Prediction of Nausea and Vomiting. <i>Toxicological Research</i> , 2012 , 28, 81-91	3.7	9
39	AIDS-related lymphoma (ARL) in Asians in the era of HAART and rituximab.. <i>Journal of Clinical Oncology</i> , 2012 , 30, e18546-e18546	2.2	
38	Clinical outcomes for cancer patients using complementary and alternative medicine. <i>Alternative Therapies in Health and Medicine</i> , 2012 , 18, 12-7	2.5	6
37	Polypharmacy in elderly patients with cancer: clinical implications and management. <i>Lancet Oncology</i> , 2011 , 12, 1249-57	21.7	167
36	Clinically relevant drug interactions between anticancer drugs and psychotropic agents. <i>European Journal of Cancer Care</i> , 2011 , 20, 6-32	2.4	32
35	Comparison of daily filgrastim and pegfilgrastim to prevent febrile neutropenia in Asian lymphoma patients. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011 , 7, 75-81	1.9	16
34	Management of tumor lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: a case series and literature review. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011 , 7, 351-6	1.9	8
33	Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy. <i>Supportive Care in Cancer</i> , 2011 , 19, 497-504	3.9	43
32	How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors?. <i>Supportive Care in Cancer</i> , 2011 , 19, 1667-74	3.9	26

31	Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. <i>Supportive Care in Cancer</i> , 2011 , 19, 1079-95	3.9	306
30	Electronic database to detect drug-drug interactions between antidepressants and oral anticancer drugs from a cancer center in Singapore: implications to clinicians. <i>Pharmacoepidemiology and Drug Safety</i> , 2011 , 20, 939-47	2.6	13
29	Development of a chemotherapy regimen interaction database for the mobile internet: detecting interactions with psychotropics through OncoRx-MI. <i>Informatics for Health and Social Care</i> , 2011 , 36, 132-46	2.7	3
28	Impact of erythropoiesis-stimulating agent prescribing at an Asian cancer center, after release of safety advisories. <i>Journal of Oncology Pharmacy Practice</i> , 2011 , 17, 350-9	1.7	
27	Breakthrough febrile neutropenia and associated complications in Non-Hodgkin's lymphoma patients receiving pegfilgrastim. <i>Acta Haematologica</i> , 2011 , 125, 107-14	2.7	16
26	Preventing oxaliplatin-induced sensory neurotoxicity: a methodology perspective. <i>Journal of Clinical Oncology</i> , 2011 , 29, e489; author reply e490-1	2.2	
25	Clinically-relevant chemotherapy interactions with complementary and alternative medicines in patients with cancer. <i>Recent Patents on Food, Nutrition & Agriculture</i> , 2010 , 2, 12-55	1.9	9
24	Drug-drug interactions between oral antiepileptics and oral anticancer drugs: implications to clinicians. <i>European Neurology</i> , 2010 , 64, 88-94	2.1	6
23	OncoRx-IQ: a tool for quality assessment of online anticancer drug interactions. <i>International Journal for Quality in Health Care</i> , 2010 , 22, 93-106	1.9	9
22	Cancer informatics for the clinician: an interaction database for chemotherapy regimens and antiepileptic drugs. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2010 , 19, 59-67	3.2	8
21	Harnessing the internet cloud for managing drug interactions with chemotherapy regimens in patients with cancer suffering from depression. <i>Acta Oncologica</i> , 2010 , 49, 1235-45	3.2	11
20	An onco-informatics database for anticancer drug interactions with complementary and alternative medicines used in cancer treatment and supportive care: an overview of the OncoRx project. <i>Supportive Care in Cancer</i> , 2010 , 18, 883-91	3.9	17
19	A prospective study to evaluate the feasibility and economic benefits of rapid infusion rituximab at an Asian cancer center. <i>International Journal of Hematology</i> , 2010 , 91, 826-30	2.3	22
18	Clinically-Relevant Chemotherapy Interactions with Complementary and Alternative Medicines in Patients with Cancer. <i>Recent Patents on Food, Nutrition & Agriculture</i> , 2010 , 2, 12-55	1.9	14
17	Patients' perspectives and safe handling of oral anticancer drugs at an Asian cancer center. <i>Journal of Oncology Pharmacy Practice</i> , 2009 , 15, 161-5	1.7	17
16	Complementary and alternative medicine (CAM) usage in Singaporean adult cancer patients. <i>Annals of Oncology</i> , 2009 , 20, 752-7	10.3	65
15	Clinical predictors of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adjuvant doxorubicin and cyclophosphamide. <i>Annals of Pharmacotherapy</i> , 2009 , 43, 444-52	2.9	47
14	Evidence-based treatment options for the management of skin toxicities associated with epidermal growth factor receptor inhibitors. <i>Annals of Pharmacotherapy</i> , 2009 , 43, 1658-66	2.9	36

13	Evaluation of Thiazolidinediones on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus: A Systematic Review. <i>Journal for Nurse Practitioners</i> , 2009 , 5, 176-184	0.6	
12	Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: a Delphi survey of oncology pharmacists. <i>Clinical Therapeutics</i> , 2009 , 31 Pt 2, 2379-86	3.5	45
11	Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2009 , 84, 414-7	7.1	42
10	Improving pharmaceutical care in oncology by pharmacoinformatics: the evolving role of informatics and the internet for drug therapy. <i>Lancet Oncology, The</i> , 2009 , 10, 1011-9	21.7	13
9	Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: profiling and comparison of two drug compendia. <i>Annals of Pharmacotherapy</i> , 2008 , 42, 1737-48 ^{2.9}		58
8	Drug interactions between chemotherapeutic regimens and antiepileptics. <i>Clinical Therapeutics</i> , 2008 , 30, 1385-407	3.5	123
7	Evolving roles of oncology pharmacists in Singapore: a survey on prescribing patterns of antiemetics for chemotherapy induced nausea and vomiting (CINV) at a cancer centre. <i>Journal of Oncology Pharmacy Practice</i> , 2008 , 14, 23-9	1.7	21
6	Liposomal doxorubicin-associated acute hypersensitivity despite appropriate preventive measures. <i>Journal of Oncology Pharmacy Practice</i> , 2007 , 13, 105-7	1.7	12
5	Systemic anticoagulant prophylaxis for central catheter-associated venous thrombosis in cancer patients. <i>Annals of Pharmacotherapy</i> , 2007 , 41, 635-41	2.9	17
4	Survey of topical oral solutions for the treatment of chemo-induced oral mucositis. <i>Journal of Oncology Pharmacy Practice</i> , 2005 , 11, 139-43	1.7	35
3	Experience with nesiritide at a community hospital. <i>American Journal of Health-System Pharmacy</i> , 2004 , 61, 1337-8	2.2	1
2	Pulmonary edema and possible pneumonitis associated with celecoxib. <i>Annals of Pharmacotherapy</i> , 2004 , 38, 1086	2.9	0
1	Diet and exercise advice and referrals for cancer survivors: an integrative review of medical and nursing perspectives. <i>Supportive Care in Cancer</i> ,	3.9	0